Alkermes plc. Total Long-Term Debt
Alkermes plc. (ALKS) had Total Long-Term Debt of $1.52 billion as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-07-28
- 2026-06-30: Long-term Debt $1.52B.
- 2026-03-31: Long-term Debt $1.52B.
- 2016-12-31: Long-term Debt $283.67M.
- 2016-09-30: Long-term Debt $285.58M.
| Period end | Long-term Debt | Long-term Debt as first filed |
|---|---|---|
| 2026-06-30 | $1.52B 10-Q · filed 2026-07-28 | |
| 2026-03-31 | $1.52B 10-Q · filed 2026-05-05 | |
| 2016-12-31 | $283.67M 10-K · filed 2017-02-17 | |
| 2016-09-30 | $285.58M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $347.03M 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $348.49M 10-Q · filed 2016-04-28 | |
| 2015-12-31 | $349.94M 10-K · filed 2017-02-17 | |
| 2015-09-30 | $353.22M 10-Q · filed 2015-10-29 | |
| 2015-06-30 | $354.81M 10-Q · filed 2015-07-30 | |
| 2015-03-31 | $356.39M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $355.76M 10-K · filed 2016-02-25 | $357.97M 10-K · filed 2015-02-24 |
| 2014-09-30 | $359.55M 10-Q · filed 2014-10-29 | |
| 2014-06-30 | $361.13M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $362.71M 10-Q · filed 2014-04-30 | |
| 2013-12-31 | $364.29M 10-K · filed 2015-02-24 | |
| 2013-09-30 | $365.87M 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $367.44M 10-Q · filed 2013-07-25 | |
| 2013-03-31 | $369.01M 10-KT · filed 2014-02-27 | |
| 2012-12-31 | $369.10M 10-Q · filed 2013-01-31 | |
| 2012-09-30 | $370.60M 10-Q · filed 2012-11-01 | |
| 2012-06-30 | $444.18M 10-Q · filed 2012-07-26 | |
| 2012-03-31 | $444.46M 10-K · filed 2013-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |